Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

2.

Adverse effects of atypical antipsychotics : differential risk and clinical implications.

Haddad PM, Sharma SG.

CNS Drugs. 2007;21(11):911-36. Review.

PMID:
17927296
3.

Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients.

Correll CU.

Int Rev Psychiatry. 2008 Apr;20(2):195-201. doi: 10.1080/09540260801889179. Review.

PMID:
18386212
4.

Balancing efficacy and safety in treatment with antipsychotics.

Correll CU.

CNS Spectr. 2007 Oct;12(10 Suppl 17):12-20, 35. Review.

PMID:
17934385
5.

Use of antipsychotics in children and adolescents.

Findling RL, Steiner H, Weller EB.

J Clin Psychiatry. 2005;66 Suppl 7:29-40. Review.

6.
7.

Some adverse effects of antipsychotics: prevention and treatment.

Lader M.

J Clin Psychiatry. 1999;60 Suppl 12:18-21. Review.

8.

Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.

Maayan L, Correll CU.

J Child Adolesc Psychopharmacol. 2011 Dec;21(6):517-35. doi: 10.1089/cap.2011.0015. Epub 2011 Dec 13. Review.

PMID:
22166172
9.

Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.

Correll CU, Penzner JB, Parikh UH, Mughal T, Javed T, Carbon M, Malhotra AK.

Child Adolesc Psychiatr Clin N Am. 2006 Jan;15(1):177-206. Review.

PMID:
16321730
10.
11.

The efficacy, safety, and tolerability of antipsychotics in the elderly.

Maixner SM, Mellow AM, Tandon R.

J Clin Psychiatry. 1999;60 Suppl 8:29-41. Review.

12.

Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns.

Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C.

Eur Neuropsychopharmacol. 2009 Sep;19(9):629-35. doi: 10.1016/j.euroneuro.2009.04.008. Epub 2009 May 24. Review.

PMID:
19467582
13.

Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies.

Zuddas A, Zanni R, Usala T.

Eur Neuropsychopharmacol. 2011 Aug;21(8):600-20. doi: 10.1016/j.euroneuro.2011.04.001. Epub 2011 May 6. Review.

PMID:
21550212
14.

Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents.

Correll CU, Carlson HE.

J Am Acad Child Adolesc Psychiatry. 2006 Jul;45(7):771-91. Review.

PMID:
16832314
15.

Adverse effects of antipsychotic medications.

Muench J, Hamer AM.

Am Fam Physician. 2010 Mar 1;81(5):617-22. Review.

16.

Antipsychotics in pediatric and adolescent patients: a review of comparative safety data.

Ben Amor L.

J Affect Disord. 2012;138 Suppl:S22-30. doi: 10.1016/j.jad.2012.02.030. Epub 2012 Mar 8. Review.

PMID:
22405602
17.

Use of atypical antipsychotics in the treatment of autistic disorder.

Stachnik JM, Nunn-Thompson C.

Ann Pharmacother. 2007 Apr;41(4):626-34. Epub 2007 Mar 27. Review.

PMID:
17389666
18.

Prolactin-related and metabolic adverse effects of atypical antipsychotic agents.

Henderson DC, Doraiswamy PM.

J Clin Psychiatry. 2008;69 Suppl 1:32-44. Review.

19.

Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.

Bishara D, Taylor D.

Drugs. 2008;68(16):2269-92. doi: 10.2165/0003495-200868160-00002. Review.

PMID:
18973393
20.

Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.

Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP.

J Clin Psychiatry. 2009 Jan;70(1):104-12. Epub 2008 Nov 18. Review.

PMID:
19026265
Items per page

Supplemental Content

Write to the Help Desk